Media

March 20, 2025: DSMB Confirms MaaT013 Efficacy/Benefit in GI-aGvHD – Cancer Network

Date : March 20, 2025

To read article, click here

March 18, 2025: MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease

March 27, 2025: MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results